Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Treatment
Reimbursement Bladder Cancer advances with the assignment of a permanent HCPCS J-code for INLEXZO™ (gemcitabine intravesical system), effective April 1, 2026. This standardized billing code simplifies reimbursement bladder cancer treatment for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Permanent J-Code Removes Billing Obstacles
The transition from temporary to permanent J9183 coding directly tackles long-standing reimbursement bladder cancer challenges that have slowed adoption of novel therapies. The unique code provides a clear, standardized identifier for both government and commercial payers as well as physician practices, streamlining claims submission and reducing administrative burden for healthcare providers.
Stakeholder Voices on Improved Patient Access
Johnson & Johnson’s Chief Operating Officer, North America, stressed that reimbursement navigation should not block access to therapies that can change disease outcomes. A representative from Minnesota Urology noted that permanent codes can help reduce patient anxiety caused by inconsistent billing. The Bladder Cancer Advocacy Network (BCAN) welcomed the progress, stating that new treatment options backed by permanent billing codes offer meaningful advancement for patients who have experienced BCG failure.
FDA Approval and Clinical Foundation
INLEXZO received FDA approval in September 2025 based on results from Cohort 2 of the SunRISe-1 clinical trial. It is the first and only FDA-approved intravesical drug-releasing system designed for office-based placement without general anesthesia, delivering controlled, extended release of gemcitabine directly into the bladder.
The permanent J-code assignment by the Centers for Medicare & Medicaid Services (CMS) follows this approval and becomes effective April 1, 2026. INLEXZO enables physicians to use J9183 when submitting claims, subject to individual payer policies.
Safety Data and Disease Progression Insights
Trial safety data showed serious adverse reactions in 24% of patients, with urinary tract infection, hematuria, pneumonia, and urinary tract pain occurring in more than 2% of participants. Fatal adverse reactions were reported in 1.2% of patients. Additionally, 8% of evaluable patients progressed to muscle-invasive disease.
Economic Impact on Bladder Cancer Care
By simplifying billing processes, the permanent code is expected to increase provider adoption of this bladder-sparing option for patients who have failed BCG therapy. This development supports value-based care and creates opportunities to generate real-world evidence on treatment patterns, healthcare resource use, and long-term outcomes in BCG-unresponsive NMIBC.
Johnson & Johnson’s J&J withMe patient support program complements the coding milestone by providing cost support, care navigation, and educational resources to address remaining affordability barriers.
